Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Prevention of Pneumonia.
Loo, Jennifer D. MPH *; Conklin, Laura MD *; Fleming-Dutra, Katherine E. MD *+; Deloria Knoll, Maria PhD ++; Park, Daniel E. MSPH ++; Kirk, Jennifer MSc [S]; Goldblatt, David MBChB, PhD [P]; O'Brien, Katherine L. MD, MPH, ++; Whitney, Cynthia G. MD, MPH *
[Miscellaneous Article]
Pediatric Infectious Disease Journal.
33 Supplement 2, Optimum Dosing of Pneumococcal Conjugate Vaccine For Infants : A Landscape Analysis of Evidence Supportin g Different Schedules:S140-S151, January 2014.
(Format: HTML, PDF)
Background: Pneumonia is the leading cause of morbidity and mortality among children <5 years of age globally. Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule.
Methods: We conducted a systematic review of studies published from 1994 to 2010 (supplemented post hoc with studies from 2011) documenting the effect of PCV dosing schedules on clinical and radiologically confirmed pneumonia, pneumococcal pneumonia and empyema among children of ages targeted to receive vaccine. Data on 2- and 3-dose schedules were included. Percent change of pneumonia incidence rates from baseline to most recent year post-PCV introduction was calculated.
Results: We identified 42 primary citations that evaluated PCV schedules and pneumonia. Thirty-seven (88%) were from North America, Europe or Australia; 37 (88%) evaluated PCV7 and 1 (2%) PCV10. Two studies (both observational) compared multiple schedules within the study. We found evidence of reduced clinical and radiologically confirmed pneumonia incidence for all schedules, including 2 1 (1 nonrandomized trial, 5 observational studies), 3 0 (5 randomized trials, 2 observational studies) and 3 1 (5 clinical trials, 24 observational studies) schedules. The magnitude of disease impact did not differ among schedules. Evidence for impact on pneumococcal pneumonia and empyema varied.
Conclusions: All schedules (2 1, 3 0 and 3 1) reduced clinical and radiologically confirmed pneumonia. Quantifying differences in pneumonia disease impact between schedules was difficult due to heterogeneity among studies in design, case definition and population. These findings support World Health Organization recommendations for 3-dose schedules administered as either 3 0 or 2 1 regimens. Pneumonia impact data are still needed on expanded serotype PCV products, developing country settings and the role for a booster dose.
(C) 2014 by Lippincott Williams & Wilkins, Inc.
